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DTP VACCINE RELATED INJURY: AN




Each year an estimated 15,000,000 doses of diptheria-tetanus-pertussis
vaccine ("DTP" or "DPT") are administered to the children of this nation
to immunize them from potentially fatal diseases.' Approximately one in
310,000, or sixty-one of the children immunized, die or suffer severe neuro-
logic complications2 including prolonged convulsions, encephalitis, or en-
cephalopathy.3 The pertussis component of the vaccine causes these
disorders; the pertussis disease, more commonly known as whooping cough,
can be fatal. Prior to the availability of a vaccine, deaths in the United
States resulting from pertussis were seventy per million in the 1920's.4 Vac-
cine use reduced this figure to seven per million by the mid 1950's.5 Two
scientists at the Centers for Disease Control estimate that use of the DTP
vaccine prevents approximately 322,000 cases of pertussis per year.6 An es-
timated four hundred fifty-seven persons per year would die from the disease
without an immunization program, yet, use of the vaccine reduces this figure
to forty-four.' There is, then, a strong incentive to vaccinate. However,
along with a mass immunization program comes the question of who should
bear the burden of paying for vaccine related injuries.
1. This figure is based on multiplying the approximate number of children born each
year (3,000,000) by the number of doses each child must receive (five). National Childhood
Vaccine-Injury Compensation Act of 1985. Hearings on S. 827 Before the Senate Comm. on
Labor and Human Resources, 99th Cong., 1st Sess. 327 (1985) [hereinafter Hearings] (state-
ment of Martin H. Smith, M.D., F.A.A.P.).
2. Miller, Ross, Alderslade, Bellman & Rawson, Pertussis Immunization and Serious
Neurological Illness in Children, 282 BRIT. MED. J. 1595-99 (1981). This figure is a source of
controversy, however, because the study observed children who received a different vaccine
than the one administered in the United States. An earlier UCLA study, published in 1980,
suggested a much higher proportion of deaths or permanent injury; 1: 1750. H. COULTER &
B. FISHER, DPT: A SHOT IN THE DARK 371-75 (1985).
3. Encephalitis is inflammation of the brain, encephalopathy is any disease of the brain.
STEDMAN'S MEDICAL DICTIONARY 408, 410 (22d ed. 1972).
4. H. COULTER & B. FISHER, supra note 2.
5. Id.
6. Hinmon & Koplan, Pertussis and Pertussis Vaccine: Reanalysis of Benefits, Risks and
Costs, 251 J. A.M.A. 3112, Table 5 (1984).
7. Id.
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A compensation program for those who are injured as a result of vaccina-
tion does not currently exist in the United States on the federal level.' Be-
cause childhood immunization is one of the most successful preventive
public health programs, 9 many people believe that society should provide
support for those who have undertaken a risk and suffered adverse conse-
quences for the benefit of all.' ° A concerned group of parents, whose chil-
dren were injured as a result of DTP vaccination, formed an organization
called Dissatisfied Parents Together, to lobby for legislation authorizing a
federal compensation program. Senator Paula Hawkins, in April 1985, pro-
posed such legislation, which was endorsed by the American Academy of
Pediatrics." This measure directed the establishment of a compensation
plan and also sought to guarantee parents the right to judicial relief. Be-
cause the Hawkins' bill availed parents of an opportunity to seek judicial
relief, vaccine manufacturers opposed this legislation.12
Manufacturers have been held strictly liable by courts in vaccine injury
cases.13 The Restatement (Second) of Torts § 402A' 4 imposes strict liability
on the seller who markets a product unreasonably dangerous to the con-
sumer. Comment k of that section, however, makes an exception to the rule
providing:
There are some products which, in the present state of human
knowledge, are quite incapable of being made safe for their in-
tended and ordinary use . . . . The same is true of many other
drugs, vaccines, and the like . . . . The seller of such products,
again with the qualification that they are properly prepared and
marketed, and proper warning is given, where the situation calls
for it, is not to be held strictly liable for the unfortunate conse-
quences attending their use, merely because he has undertaken to
supply the public with an apparently useful and desirable product,
8. The state of California has a compensation plan for those who are injured as a result
of mandatory vaccination. CAL. HEALTH & SAFETY CODE § 429.35 (West 1979).
9. Hearings, supra note 1, at 118 (statement of Dr. James 0. Mason, Acting Assistant
Secretary for Health, and Director, Centers for Disease Control, Department of Health and
Human Services).
10. Id. at 223, 248, 326 (statements of Robert L. Willmore, Deputy Assistant Attorney
General, Civil Division; Robert B. Johnson, President, Lederle Laboratories Division, Ameri-
can Cyanamid Company; Martin H. Smith, M.D., F.A.A.P).
11. S. 827, 99th Cong., 1st Sess. (1985). The bill died in committee.
12. Hearings, supra note 1, at 250, 273, 312-13 (statements of Robert B. Johnson, Presi-
dent, Lederle Laboratories Division, American Cyanamid Company; David J. Williams, Vice
President, Connaught Laboratories, Inc.; Charles F. Hagan, Vice President, American Home
Products Corporation).
13. See infra p. 235 & note 16.
14. RESTATEMENT (SECOND) OF TORTS § 402A (1965).
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attended with a known but apparently reasonable risk.15
This exception would appear to protect DTP manufacturers from liability;
however, courts have not so held. A number of courts in the 1960's held the
manufacturer responsible for vaccine related injury. 16 Because many recent
decisions are either unreported or sealed, a current statement as to why com-
ment k does not protect manufacturers is unavailable.' 7
From 1978-1984 one hundred forty suits were filed against the three cur-
rent manufacturers of DTP vaccine; more than half in 1984, with an average
specified claim of $46.5 million. 8 Jury awards have been significant in DTP
injury cases,' 9 and manufacturers are making increasingly large settlements
with victims.2 ° The current trend is for manufacturers to settle cases then
request that the court records be sealed and the amount of the settlement
kept secret.2 '
It is precisely because of these significant jury awards that some manufac-
turers have withdrawn from the market. 22 The difficulty in obtaining liabil-
ity insurance has prompted the withdrawals; the underwriters are no more
willing to shoulder the expense for these claims than are the manufacturers
themselves. As a result, the drug companies, like Dissatisfied Parents To-
gether, have lobbied for a federal compensation program. In March of 1985,
15. Id. comment k (emphasis added).
16. See, e.g., Tinnerholm v. Parke-Davis & Co., 285 F. Supp. 432 (S.D.N.Y. 1968), modi-
fied, 411 F.2d 48 (2d Cir. 1969); Stromsodt v. Parke-Davis & Co., 257 F. Supp. 991 (D.N.D.
1966), aff'd, 411 F.2d 1390 (8th Cir. 1969); Gottsdanker v. Cutter Laboratories, 182 Cal. App.
2d 602, 6 Cal. Rptr. 320 (1960).
17. The U.S. Court of Appeals recently certified a question construing the principles of
§ 402A comment k to the Idaho Supreme Court. Toner v. Lederle Laboratories, 779 F.2d
1429 (9th Cir. 1986).
18. Hearings, supra note 1, at 156 (statement of Dr. James 0. Mason, Acting Assistant
Secretary of Health, and Director, Centers for Disease Control, Department of Health and
Human Services).
19. In the unreported case of Toner v. Lederle Laboratories, No. 80-1245 (D. Idaho Apr.
23, 1984), the parents of a child who developed a rare brain disorder after receiving a DTP
shot alleged that the whole cell vaccine manufactured by Lederle was not as safe as the split
cell vaccine manufactured by Eli Lilly. The jury awarded $1.2 million to the plaintiff.
20. See, e.g., Chickasuye v. Connaught & Lederle, No. 75439 (1st Cir. Haw. Sept. 24,
1985) (settlement with parents of child left with severe retardation and seizures following DTP
shot of $4.3 million guaranteed with $1.65 million in cash and annuities); Holcomb v. United
States & Richardson-Merrell, No. 79-2376 (S.D. W. Va. May 5, 1982) (settlement of $600,000
with parents of infant who suffered encephalopathy after DTP shot).
21. Dissatisfied Parents Together News 3 (Winter 1986) (available from the editorial of-
fices of J. CONTEMP. HEALTH L. & POL'Y, Catholic University of America, Columbus School
of Law, Washington, D.C. 20064).
22. Hearings, supra note 1, at 271, 311 (statements of Robert B. Johnson, President, Led-
erie Laboratories Division, American Cyanamid Company; David J. Williams, Vice President,
Connaught Laboratories, Inc.; Charles F. Hagan, Vice President, American Home Products
Corporation).
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Congressman Madigan proposed legislation which, unlike the Hawkins' ini-
tiative, would have empowered an independent panel to render compensa-
tion decisions. 23 The parents' group opposed this bill because it limited
damage awards and deprived them of a right to sue in court.24
The public interest in maintaining childhood vaccination programs led to
yet another proposal. 25 Two drug companies, Wyeth and Connaught, with-
drew from the production and supply market. Subsequently, in 1984, the
third commercial source of DTP vaccine, Lederle, encountered production
difficulties. The result was a vaccine shortage which threatened the public
safety.26 Compounding the problem was an announcement by Lederle that
it was encountering difficulties in obtaining a renewal of its liability insur-
ance. 27 These events led Health and Human Services Secretary Margaret
Heckler to establish a Working Group on vaccine supply and liability.
28
The efforts of this group resulted in a proposal by the Administration which
would protect the supply of childhood vaccines.2 9 To that end, the bill pro-
posed a cap on the damage recoveries for injuries due to certain vaccines.
The bill, introduced by Congressman Tauke in March 1986, was not a com-
pensation program; it would have simply regulated damage awards resulting
from suits in federal and state courts.3°
All three proposals sought adequate compensation for vaccine related in-
juries and protection of the vaccine supply. The proposals of the parents and
the manufacturers are similar to the indemnity plan established for the swine.
flu vaccine in 1976.31 This comment will examine the proposals in light of
the swine flu model and will compare them for similarities and differences.
23. H.R. 1780, 99th Cong., 1st Sess. (1985). This bill died in committee.
24. Hearings, supra note 1, at 119 (statement of Jeffrey H. Schwartz, President, Dissatis-
fied Parents Together).
25. H.R. 4777, 99th Cong., 2d Sess. (1986). This bill died in committee.
26. Hearings, supra note 1, at 119 (statement of Dr. James 0. Mason, Acting Assistant




29. H.R. 4777, supra note 25.
30. A limitation on damage awards resulting from a nuclear accident involving nuclear
energy was attempted in the Price Anderson Act, 42 U.S.C. § 2210(e) (1982). That portion
limiting damages was held constitutional by the Supreme Court in Duke Power Co. v. Caro-
lina Envtl. Study Group, Inc., 438 U.S. 59 (1978) (The court relied on a minimal scrutiny
rational basis test to uphold the limitation on damages.). This would set a precedent for any
challenge to congressional legislation limiting damage awards in vaccine injury cases.
31. National Swine Flu Immunization Program of 1976, Pub. L. No. 94-380, 90 Stat.
1115 (codified prior to amendment at 42 U.S.C. § 247b (1982)) [hereinafter Swine Flu
Program].
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Finally, it will estimate what problems might arise with each legislative
scheme, if enacted, and suggest methods for resolving the problems.
II. THE SWINE FLU LEGISLATION
A. History
In February 1976, a number of soldiers at Fort Dix were infected by a
New Jersey influenza ("swine flu").3 2 There was serious concern that this
was the same type of influenza that caused the winter of 1918 pandemic.
For this reason, then-President Gerald Ford encouraged development of a
vaccine program to be implemented in the fall of that year, with the govern-
ment appropriating money to test a vaccine.3 3 The vaccine manufacturers
developed a vaccine but opposed a mass immunization program because of
the possibility of their exposure to liability for injuries that might occur.34
The insurance companies agreed and either cancelled or greatly limited the
liability coverage of the manufacturers.35 The proposed National Swine Flu
Immunization Program bill was accordingly stalled because Congress did
not understand the hesitancy on the part of the insurance companies.3 6 Due
in large part to the efforts of President Ford, Congress finally passed the bill
on August 10, 1976, implementing the program and providing compensation
for vaccine related injuries.37
Congress agreed that the United States would indemnify the manufactur-
ers for strict liability, but not for negligence. 38 This is precisely what the
manufacturers wanted because their concern was for claims arising under
the Restatement (Second) of Torts § 402A. 39 The Swine Flu Act provided
that the Federal Tort Claims Act ("FTCA") ° would be the vehicle for as-
serting claims against the United States government arising out of the swine
flu program.4 ' Under the FTCA, the United States is liable for injury "if a
private person[,] would be liable to the claimant in accordance with the law
32. Shapo, Swine Flu and Legal Policy, 63 A.B.A. J. 51 (1977).
33. Id.
34. Id. at 52.
35. Id.
36. Id.
37. Swine Flu Program, supra note 31, 90 Stat. 1115 (codified prior to amendment at 42
U.S.C. § 247b).
38. Id.
39. Proposed National Swine Flu Vaccination Program: Hearings on President's Proposal to
Initiate National Immunization Program to Insure that Every Citizen may be Protected Against
the Swine Flu Influenza, Before the Subcomm. on Health and the Environment of the House
Comm. on Interstate and Foreign Commerce, 94th Cong., 2d Sess. 9-14 (1976).
40. Federal Tort Claims Act, 28 U.S.C. §§ 2671-2860 (1982).
41. Swine Flu Program, supra note 31, at § 2(k)(2)(A), 90 Stat. at 1115 (codified prior to
amendment at 42 U.S.C. § 247b).
1987]
238 Journal of Contemporary Health Law and Policy [Vol. 3:233
of the place where the act or omission occurred."
42
The Swine Flu Act provided further that the United States could be held
strictly liable for the acts or omissions of a program participant.43 A "pro-
gram participant" was defined as any manufacturer or distributor of the vac-
cine, the public or private agency that provided innoculation, and medical
and health personnel who assisted in providing innoculation without charge,
in compliance with informed consent requirements.' This definition was
important to the legislative liability scheme because the United States was
not to be considered a program participant, therefore, actions based on its
acts or omissions were governed by the normal procedures of the FTCA.45
The Attorney General was required to defend any claim brought against
the federal government, its employees, or a program participant.46 Once the
Attorney General certified the claim, the action would be against the United
States.47 If an action were brought in a district court of the United States,
the United States would be substituted as a party defendant once the claim
was certified;4" if an action were brought in a state court, the Act provided
for removal to a federal district court.49 Finally, the Act stated that claims
under it would be the exclusive remedy for all injuries arising from the swine
flu program.5° These provisions allowed the federal government to handle
all claims which would arise due to injuries related to immunizations under
the program.
B. Implementation
The swine flu immunization program continued to experience difficulties
42. 28 U.S.C. § 1346(b) (1982).
43. Swine Flu Program, supra note 31, 90 Stat. 1113 (codified prior to amendment at 42
U.S.C. § 247b). "The United States shall be liable with respect to claims submitted ... for
personal injury or death arising out of the administration of the swine flu vaccine under the
swine flu program and based upon the act or omission of a program participant .... "
44. Swine Flu Program, supra note 31, at § 2(k)(4), 90 Stat. at 1116 (codified prior to
amendment at 42 U.S.C. § 247b).
45. Baynes, Liability for Vaccine Related Injuries: Public Health Considerations and Some
Reflections on the Swine Flu Experience, 21 ST. Louis U.L.J. 44, 67 (1977).
46. Swine Flu Program, supra note 31, at § 2(k)(4), 90 Stat. at 1116 (codified prior to
amendment at 42 U.S.C. § 247b).
47. Swine Flu Program, § 2(k)(5)(A), 90 Stat. at 1116 (codified prior to amendment at 42
U.S.C. § 247b).
48. Id.
49. Id. at § 2(k)(5)(B), 90 Stat. at 1116 (codified prior to amendment at 42 U.S.C. § 247b).
50. Id. at § 2(k)(3), 90 Stat. at 1116 (codified prior to amendment at 42 U.S.C. § 247b)
This provision was held constitutional in Jones v. Wyeth Laboratories, 457 F. Supp. 35 (W.D.
Ark. 1978). The court held that the immunization program could not have proceeded without
the swine flu legislation and the plaintiff's right to equal protection was not violated because
the Act was rationally related to a legitimate governmental goal.
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after implementation. The public was aware of the vaccine, but failed to
submit to the innoculation.5 1 Three vaccinees died immediately after the
program began, heightening concern over its safety.5 2 The discovery that
the neurologic disorder known as Guillian-Barre Syndrome ("GBS") was a
possible side effect led to the termination of the program in December
1976."3 By the summer of 1981, some 4,000 administrative claims had been
filed.54
Because of the massive amount of litigation which arose, the Judicial
Panel on Multi-District Litigation ordered all of the cases consolidated for
pre-trial discovery.55 At the end of the discovery stage, the United States
stipulated that it would concede liability in cases where GBS occurred a
short time after receipt of the shot.5 6 Thus, only causation and damages
remained open issues at trial.57 Once the cases were remanded after discov-
ery, most district courts elected either to assign all the cases to one judge or
to allow the cases to stay with the judge who was assigned when the case was
filed.5 8 A liaison office was opened in Washington, D.C. to handle commu-
nications between the courts, the plaintiffs, and the government attorneys.59
C. Litigation
The 4,000 claims filed initially resulted in more than 1,500 cases in federal
district courts. 60 By 1985 the amount of claims filed against the federal gov-
ernment totalled $3,000,000,000.61 Examples of some recent cases will serve
to illustrate how the program works.
With regard to diagnosis and causation the courts generally have not held
the government liable for disorders other than GBS.62 When liability was
51. Baynes, supra note 45, at 69.
52. Id.
53. Rheingold & Shoemaker, The Swine Flu Litigation, 8 LITIGATION 28 (1981).
54. Huber, Safety and Second Best: The Hazards of Public Risk Management in the
Courts, 85 COLUM. L. REV. 277, 287 (1985).
55. Pursuant to the multi-district litigation rules in 28 U.S.C. § 1407 (1982). Rheingold &
Shoemaker, supra note 53, at 29.
56. Stipulation and Final Pre-Trial Order, In re Swine Flu Immunization Prods. Liab.
Litig., 446 F. Supp. 244 (D.D.C. 1979).




61. Id. For further information on Swine Flu litigation contact Torts Branch, Civil Divi-
sion, Department of Justice, Washington, D.C.
62. See, e.g., Zeck v. United States, 720 F.2d 534 (8th Cir. 1983) (A brain stem stroke
following swine flu innoculation was found not a result of the shot when the victim smoked
heavily, had a history of vascular disease, and was under great stress.); Gaul v. United States,
1987]
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not stipulated, the plaintiff had to prove it.63 In non-GBS cases the issue
arose in connection with the informed consent requirement of the statute.
64
In one case, because the danger of serum sickness from the swine flu vaccine
was known to the medical community prior to the 1976 immunization pro-
gram, the government was held liable for failure to warn of this specific risk
when the plaintiff contracted serum sickness subsequent to receipt of the
65vaccine.
The issue of damages was handled in the same manner as in any trial.
Plaintiffs have been allowed to recover for past and future medical expenses,
lost wages, future and past earnings, present and future pain, and suffering to
the extent allowed under the applicable state law.66
D. Swine Flu Legislation: A Good Model?
A report issued in March 1977 critiquing the swine flu model stated that
the federal tort procedure of the Swine Flu Act was "inappropriate for a
long-term national policy. ' '67 First, by requiring proof of fault for all claims
under the law of the state in which an alleged act or omission occurred, the
Act subjects liability to potentially different interpretations and standards in
all the states.68 The report found this inconsistent with the concept of a
national policy on immunization. Second, the report indicated that the tort
procedure actually served as a disincentive to immunization because of the
expense of litigation and the burden of proof required.69
The government assumed the role of principal defendant under the swine
flu model. Whether this is essential to any compensation program is uncer-
tain. Where, as with the swine flu, there is a possible threat of pandemic, the
government may appropriately consider itself required to implement a vacci-
nation program and accept the consequences of that decision by becoming
582 F. Supp. 1122 (D. Del. 1984) (Plaintiff failed to prove causation between vaccination and
contraction of swine flu.).
63. See, e.g., Zeck, 720 F.2d 534; Gaul, 582 F. Supp. 1122.
64. Swine Flu Program, supra note 31, at § 2(j)(1)(F), 90 Stat. at 1113.
65. Petty v. United States, 740 F.2d 1428 (8th Cir, 1984). Contra, In re Swine Flu Immu-
nization Prods. Liab. Litig., 533 F. Supp. 703 (D. Utah 1982).
66. See, e.g., McDonald v. United States, 555 F. Supp. 935 (M.D. Pa. 1983) (Plaintiff's
claim must be supported by a reasonable basis for calculation.); Sulesky v. United States, 545
F. Supp. 426 (S.D. W. Va. 1982) (Plaintiff permitted to recover damages to the extent that she
was able to prove with reasonable degree of medical certainty that they were proximately
caused by her condition.).
67. OFFICE OF THE ASSISTANT SECRETARY FOR HEALTH, DEPARTMENT OF HEALTH,
EDUCATION AND WELFARE, REPORTS AND RECOMMENDATIONS OF THE NATIONAL IMMU-
NIZATION WORK GROUP ON LIABILITY 35 (Mar. 11, 1977).
68. Id. at 37.
69. Id.
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the principal defendant in cases where individuals are injured as a result of
the program. 7° Given the increasing number of lawsuits pending against
DTP manufacturers and the reluctance of the insurance industry to under-
write liability, the federal government may have to face the issue of a na-
tional compensation program in the near future.
Although a form of absolute liability has been developing in drug product
liability suits, the swine flu model did not embrace that theory.7' The theory
received attention particularly in the area of vaccines. 72 The underlying pol-
icy of the theory is that compensation is justified for vaccine related injuries
simply because society has received a great benefit. 73 Thus, the injury itself
may establish proof of a defect. 74 The swine flu model, unwisely, did not
address the issue of whether recovery should be contingent on the fact of
injury or should be based on proof of defect." In short, victims of swine flu
vaccine injuries must litigate "within the context of a body of laws flounder-
ing in the grey area between strict liability and absolute liability. ' '76 These
criticisms of the swine flu model are of considerable importance in develop-
ing a satisfactory compensation program for those persons injured by DTP
vaccinations.
III. PROPOSED DTP VACCINE INJURY COMPENSATION
LEGISLATION
A. History
Forty-four states currently require pertussis vaccination prior to school
entry. 77 An exception is allowed in almost all of these jurisdictions if a phy-
sician determines that receipt of the vaccine would be detrimental to a
child's health.78 Some states permit an unvaccinated child to attend school
based on an objection to the vaccine by a parent; in some cases only a reli-
gious objection is recognized,7 9 while in others, a personal belief opposing
70. Shapo, supra note 32.
71. 2 DIXON, DRUG PRODUCT LIABILITY § 9.08(1) (1974).
72. Id.
73. Baynes, supra note 45, at 70.
74. Id.
75. Id. at 74.
76. Id.
77. Hinmon, The Pertussis Vaccine Controversy, 99 PuB. HEALTH REP. 255 (1984).
78. See, e.g., DEL. CODE ANN. tit. 14, § 131(a)(5) (1981) ("Provisions for exemption from
any or all of the immunization programs ... upon a written statement from a physician ...
stating that the enrollee should not receive the prescribed immunization ... because of the
reasonable certainty of a reaction detrimental to that person .... ") See also CAL. HEALTH &
SAFETY CODE § 3385 (West 1979).
79. See, e.g., MD. HEALTH-GEN. CODE ANN. § 18-403(a)(2) (1982) ("the Department
may not require the immunization of an individual if ... the individual's parent or guardian
1987]
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immunization is also permitted.8° In January 1985, Maryland passed a
model bill on pertussis.8 ' Among other provisions, the bill places a duty on
health care providers to warn of problems which may result from receipt of
the vaccine.82
To date, California is the only state which has legislation providing com-
pensation to victims with vaccine related injuries.83 It is not clear, however,
that this is the best method for handling such injuries. Although immuniza-
tion is made mandatory through state laws, federal legislation has been pro-
posed to handle the problem of compensating vaccine related injuries.
In order to ascertain the policy disincentives to the enactment of individ-
ual state compensation plans, it is necessary to examine the policy and pur-
pose underlying the three federal proposals. Protection of the childhood
vaccine supply, establishment of predictability for the insurance companies,
and compensation for victims with vaccine related injuries motivate the fed-
eral plans.84 Policy concerns include public health protection, an adequate
supply of vaccine and attraction of additional suppliers coupled with the
realization that continuing punitive damage awards may drive all suppliers
out of the market.85
Punitive damages are designed to deter and to punish egregious conduct
and unacceptable behavior; 86 it has been suggested that this deterrent is un-
necessary in vaccination cases.87 Vaccines are regulated by the Food and
Drug Administration ("FDA") and provide a significant reduction in public
risk.88 Additionally, the federal government encourages states to promote
immunization programs. To that end, the government provides grants to
objects to immunization because it conflicts with the parent or guardian's bona fide religious
beliefs and practices."). See also CAL. HEALTH & SAFETY CODE § 3385 (West 1979); DEL.
CODE ANN. tit. 14, § 131(a)(5) (1981).
80. See, e.g., COLO. REV. STAT. § 25-4-903(2)(b) (1973) ("a child shall be exempt from
receiving the required immunizations: Upon submitting a statement ... that the parent...
has a personal belief that is opposed to immunizations."). See also CAL. HEALTH & SAFETY
CODE § 3385 (1979); IND. CODE § 20-8.1-7-2(a) (1981); OKLA. STAT. tit. 70, § 1210.192
(1972).
81. MD. HEALTH-GEN CODE ANN. §§ 18-328 - 18-322 (1982).
82. Id.
83. CAL. HEALTH & SAFETY CODE § 429-35 (West 1979). This statute provides compen-
sation for vaccine related injury and grants immunity from liability in the administration of the
vaccine. The grant of immunity does not, however, protect vaccine manufacturers. In Flood
v. Wyeth Labs., 183 Cal. App. 3d 1272, 228 Cal. Rptr. 700 (1986), the court held that manu-
facture of a vaccine could not be equated with administration of a vaccine.
84. S. 827, supra note 11; H.R. 1780, supra note 23; H.R. 4777, supra note 25.
85. Hearings, supra note 1, at 223 (statement of Robert L. Willmore, Deputy Assistant
Attorney General, Civil Division).
86. Id. See also BALLANTINE'S LAW DICTIONARY 1027 (3d ed. 1969).
87. Id.
88. Huber, supra note 54, at 285, 288.
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states "for preventive health service programs to immunize children against
immunizable diseases." A report to Congress by the Department of Health,
Education & Welfare ("HEW") noted that:
[W]hile each vaccinee benefits from immunization, there is also a
substantial benefit to the public at large .... Containment of dis-
ease and consequent reduction of morbidity and the complications
of disease are the control objectives of immunization programs.
Thus, the extent of public benefit depends on the breadth of public
participation. 9
Injury sustained by submission to vaccination arguably occurs in the pub-
lic interest. There are several justifications for a compensation system.
First, the injured individual has benefitted society; the derived benefits
should be sufficient to cover the costs of injury. 90 Second, the traditional
tort method for compensation may not cover the full cost of the program
because injury has occurred without fault.91 Finally, the government has
intervened directly into individual lives by promoting or requiring immuni-
zation with resulting changes that otherwise would not have occurred, espe-
cially in mandatory programs.
92
Still the question arises - why not let the states compensate victims? Sev-
eral compelling answers have been suggested. One is that childhood immu-
nization is in the national interest and national immunization programs have
been the most successful programs.93 Further, Americans are mobile and
vaccinations are needed in all states.94 Finally, uniformity of compensation
would be difficult to achieve in fifty states.95
B. Eligibility
All three proposals cover, at a minimum, the currently mandated vac-
cines, DTP, poliomyelitis ("OPV") and measles-mumps-rubella ("MMR").
The administration bill and the parents' bill96 limit compensation to these
vaccines. The manufacturers' proposal would apply compensation and tort
limits to any vaccine listed by Health & Human Services ("HHS"), as well as
89. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE, LIABILITY ARISING OUT
OF IMMUNIZATION PROGRAMS, FINAL REPORT TO CONGRESS 4 (May 1978).
90. Id. at 99.
91. Id.
92. Id. at 100.
93. AMERICAN ACADEMY OF PEDIATRICS, TASK FORCE ON COMPENSATION FOR VAC-
CINE RELATED INJURIES REPORT (Apr. 1981).
94. Id.
95. Id.
96. H.R. 4777, supra note 25, at § 312(b)(1); S. 827, supra note 11.
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any presently mandated vaccines.9 7
Eligibility for compensation varies under the plans. The swine flu model
did not in any way change the eligibility of an individual to go to court.9a
The Administration bill is the same in this respect.99 The manufacturers'
bill would have allowed anyone injured by a vaccine to file for a hearing."o
The parents' proposal determined eligibility by use of a Vaccine Injury Ta-
ble.' An individual must have received a vaccine listed in the Table,1"2
sustained an injury listed in the Table, 113 and suffered a disability which
lasted more than one year after receipt of the vaccine,"° or died, his death
due in whole or part to injuries sustained as a result of vaccination. 105 Fur-
ther, the plaintiff may not have previously collected an award from a civil
action, nor filed an action in tort.' 06 There was some concern with the Vac-
cine Injury Table included in the Hawkins' proposal, since it amounted to
legislation of causality and would not allow for easy revision as new scientific
knowledge became available.'o7 An alternative method would be similar to
that adopted under the swine flu model whereby the government stipulated
to liability in certain GBS cases.'0 8 DTP vaccination can cause several ill-
nesses." 9 Defendants (i.e., manufacturers) could stipulate to liability in
those instances in which a known illness occurs."o
C. Dispute Resolution Process
As in the swine flu model, the nature of the process remains adversarial
under the Administration's bill; the plaintiff simply goes to court."' The
parents' bill would have allowed parents to go to court,' 12 but offered a non-
adversarial alternative: compensation determined in an ex parte civil action
97. H.R. 1780, supra note 23.
98. Swine Flu Program, supra note 31, 90 Stat. at I 113 (codified prior to amendment at 42
U.S.C. § 247b).
99. H.R. 4777, supra note 25, at § 312(a).
100. H.R. 1780, supra note 23, at § 2103(a).






107. Hearings, supra note 1, at 161 (statement of Dr. James 0. Mason, Acting Assistant
Secretary for Health, and Director, Centers for Disease Control, Department of Health and
Human Services).
108. See supra note 56.
109. See supra p. 233 & note 3.
110. See supra note 55 and accompanying text.
Ill. H.R. 4777, supra note 25, at § 2103(a).
112. Id.
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in the United States District Court for the District of Columbia." 3 The
alternatives presented, however, serve only to increase the liability of manu-
facturers. Thus, given the present hesitancy of the insurance companies to
underwrite liability, it is likely that they would refuse to do so if plans such
as these were adopted.
The manufacturers' bill contemplated an adversarial process, but provided
for one that is less formal than a tort suit. A hearing panel, composed of
people selected by Secretary of HHS and remunerated by the United States
to perform such specified duties, would review claims." 4 Both the plaintiff
and the defendant would be permitted to select one member to be on the
panel from a list of persons the Secretary would provide." 5 The two mem-
bers would then meet and select a third." 6 At this point, the defendant
would have the option to either consent to be bound by the decision of the
panel or to refuse." 7 Only if the defendant refuses to be bound will the
plaintiff be allowed to go to court on the basis of traditional tort theories.
The manufacturers' bill further relieved the manufacturer of all liability
without regard to negligence." 8 An alternative method would be to make
the manufacturer liable for its negligent acts, as in the swine flu model and
thereby provide incentives for vaccine improvement and assurance that vac-
cines are manufactured in a proper manner.
D. Administrative Requirements
Administrative requirements vary under each proposal. The applicable
state or federal statute of limitations for filing a claim would have remained
the same under the administration bill." 9 The parents' bill would require
that a claim be filed within five years of the occurrence of the injury or two
years after enactment of the bill, whichever is later. 2 0 This would not apply
if the claimant did not know that the injury was compensable.' 2 ' That pro-
vision was designed to ensure that all those injured as a result of vaccination
have the opportunity to be compensated. The parents' bill also allowed the
district court 270 days to make a decision. 122 Thus, the problem of pro-
113. S. 827, supra note 11, at § 2104.
114. H.R. 1780, supra note 23, at § 2103.
115. Id. at § 2101.
116. Id.
117. Id. at § 2104.
118. Id.
119. H.R. 4777, supra note 25, at § 2103(a).
120. S. 827, supra note 11, at § 2106.
121. Id.
122. Id. at § 2104.
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tracted litigation which was present with the swine flu model would be
avoided.
The manufacturers' bill required that the claim be filed within two years
after the injury first manifested itself or two years after the date of enact-
ment, whichever is later.'2 3 This limit applied regardless of when the causal
link between injury and vaccination was discovered.' 24 Under this scheme
no deadline for a decision is provided; thus, the possibility of protracted liti-
gation exists.
E. Limitation On Awards
Both the parents' and the manufacturers' proposals established compensa-
ble damages; the latter placed a limit on them. The Administration's bill
simply placed a limit on the amount of damages which a court may award.
The parents' bill made payment of damages mandatory if the claimant is
found eligible for compensation. 125 Compensable damages would include
health, education, custodial care and service expenses, and rehabilitation
necessary for the person "to achieve the maximum potential and enjoyment
of life of such person."' 126 In addition, compensation would be available for
death, 127 as well as for pain and suffering of the injured person. Compensa-
tion amounts would be paid from a fund to which both the federal govern-
ment and the manufacturers would contribute, the latter by way of a
surcharge on vaccines.'
2 8
Under the manufacturers' proposal, the hearing panel would compensate
for health, education, custodial care and expenses, loss of earnings, and pain
and suffering up to an aggregate amount of $1,000,000. Also, awards for
pain and suffering would not exceed $100,000.129 The bill provided for com-
pensation to be paid by vaccine manufacturers. 30 A concern with those
provisions is the ceiling placed on compensable damages. In cases where a
child becomes severely handicapped, the medical expenses alone often leave
families on the brink of financial disaster.13 ' It may be better to allow for
payment of all reasonably incurred medical expenses without limit.
The Administration's bill places no limit on damages which the court may
123. H.R. 1780, supra note 23.
124. Id.
125. S. 827, supra note 11, at § 2104(f)(1).




130. H.R. 1780, supra note 23, at § 2111.
131. Hearings, supra note 1, at 326 (statement of Martin H. Smith, President, American
Academy of Pediatrics).
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award for past and future economic loss including expenses of health and
custodial care, rehabilitation, loss of earnings, loss of homemaker expenses
and burial expenses.132 No other damages may be awarded in excess of
$100,000.133 These limits would be applied to all actions filed in state or
federal courts and pre-empt any state law with inconsistent provisions. 34
This bill would not change the existing tort system: if found liable, the de-
fendant in the suit would pay damages.
All three proposals would eliminate punitive damages. The only excep-
tion to this is under the parents' bill if a parent decides to go to court. In
that case, punitive damages would be allowed to the extent permitted by
state tort law.135 The elimination of punitive damages is an idea which must
be considered in the area of vaccine injury compensation because punitive
damage awards are forcing manufacturers out of the market. This type of
limitation would certainly establish predictability for the insurance under-
writers. It could also be argued that manufacturers should not be punished
for injuries which occur from vaccines which the federal government has
approved for use. On the other hand, the elimination of punitive damage
awards may remove any incentive which manufacturers have for the im-
provement of vaccines with potentially dangerous side effects, such as
pertussis.
F Model Legislation
Arguably, the best means of compensating injured vaccinees may be
through federal government action.1 36 This would eliminate the problem of
trying to establish a uniform system of compensation in fifty states. The
plan must be carefully drawn, however, so as to adequately compensate in a
timely manner those who are injured. The best means of doing this would be
to take the positive aspects of each proposal and combine them, while keep-
ing in mind the pitfalls to be avoided from the swine flu model.
The current budget problems must be considered before the implementa-
tion of any compensation plan. Given the cuts that all departments face, it
would be unwise to expect the federal government to assume liability as in
the swine flu model. 137 Similarly, setting up a hearing panel would be too
costly. 131
132. H.R. 4777, supra note 25, at § 312(b)(2).
133. Id.
134. Id.
135. S. 827, supra note 11, at § 2102.
136. See supra notes 9 & 10 and accompanying text.
137. Swine Flu Program, supra note 31, 90 Stat. 1115 (codified prior to amendment at 42
U.S.C. § 247b).
138. This was proposed in H.R. 1780, supra note 25.
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First and foremost, national legislation is needed requiring health care
providers to inform parents when the DTP vaccine is contraindicated and
what side effects may occur if the vaccine is given. Many times, parents are
either misinformed or not informed about those facts and their children suf-
fer injuries as a result.139
For suits brought, use of the existing court system is the wisest choice."
The problems which remain to be considered are time limits on decisions
and limitations on awards. Whether or not a time limit for decisionmaking
by the court is practical, it is necessary to avoid the possibility of protracted
litigation. 4' Compensable damages should include those for health, educa-
tion, custodial care, rehabilitation, loss of earnings and death expenses.142
Damages should be allowed for pain and suffering although there is a debate
as to whether or not a ceiling should be placed on them.'43
The remaining issue is whether punitive damage awards should be elimi-
nated. If the argument that society should bear the cost of injuries which
result when individuals are innoculated with federally approved vaccines for
the public good is accepted, then the elimination of punitive damages is an
acceptable premise. 44However, a total elimination would prevent the pun-
ishment of manufacturers who are negligent in producing the vaccine.'
45
Also, manufacturers would have no incentive to improve their products. 146
IV. CONCLUSION
Immunization programs are certainly vital to national public health poli-
cies. While each vaccinee benefits from immunization, there is a great bene-
fit to society as a whole. It is indisputable, however, that some individuals
are going to be injured as a result of vaccination. It may be argued that since
the general public benefits, the cost of compensating those who are injured
should be borne by society. The best means of accomplishing this may be
through federal action, although the problems which arose with the swine flu
legislation indicate that careful consideration must be given before any fed-
eral legislation is enacted.
139. Hearings, supra note 1, at 37-40 (statement of Jeffrey H. Schwartz, President, Dissatis-
fied Parents Together).
140. This is one of the methods contemplated in S. 827, supra note 11, and the only method
available in H.R. 1780, supra note 23.
141. See supra pp. 246-47.
142. All three bills provide awards for these damages. See S. 827, supra note 11, at § 2105;
H.R. 1780, supra note 23, at § 2107; H.R. 4777, supra note 25, at § 312(b)(2).
143. See supra note 142.
144. See supra notes 9-10 and accompanying text.
145. See supra p. 245-46.
146. Id.
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National legislation would establish uniformity and eliminate the
problems evident in coordinating legislation in the fifty states. The plan
must provide timely, adequate compensation for those who are injured,
while at the same time taking into account the current budget climate. To
accomplish this, one must consider the positive aspects of each of the three
proposals, while keeping in mind the difficulties with the swine flu model.
The result should be a plan which will compensate victims adequately and
will protect the national childhood vaccine supply.
V. EPILOGUE
On September 18, 1986, subsequent to submission of this comment for
publication, Senator Waxman introduced H.R. 5546, The National Child-
hood Vaccine Injury Act of 1986.147 The Act was passed by Congress on
October 18, 1986, as a part of S. 1744, an Omnibus Health Package,148 and
signed into law by President Reagan on November 14, 1986. The measure
will not go into effect, however, until a funding mechanism is enacted. It is
anticipated that funding will be accomplished by enactment of an excise tax
on each dose of vaccine given.
14 9
The program provides a national program for compensating victims of
vaccine injury. It represents a combination of the three proposals heretofore
discussed. For that reason, the arguments for and against those bills are
equally applicable to the newly enacted legislation.
A. Eligibility
Persons suffering an injury after the program begins may not file suit in
court until they have resorted to the no-fault compensation system estab-
lished by the legislation. 'o Coverage is limited in a Vaccine Injury Table to
the three currently mandated vaccinations; DTP, OPV and MMR.' 5' The
Table further limits coverage to certain injuries, disabilities, illnesses and
conditions caused by each vaccine.' 52
The injuries listed in the Table are presumed to be vaccine-related. How-
ever, the presumption may be overcome if a vaccine manufacturer or HHS
147. H.R. 5546, 99th Cong., 2d Sess. (1986).
148. The House passed the measure by a voice vote on October 17, 1986. 132 CONG. REC.
H 11,614 (daily ed. Oct. 17, 1986). The Senate passed the measure on October 18, 1986 by
voice vote. 132 CONG. REC. S17,348 (daily ed. Oct. 18, 1986).
149. National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, tit. 3, § 323(a),
100 Stat. 3755, 3784 (1986) [hereinafter Vaccine Injury Act].
150. Id. at § 2121, 100 Stat. at 3772.
151. Id. at § 2114(a), 100 Stat. at 3764-65.
152. Id.
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submits evidence that a particular injury is not vaccine-related.' 5 3 Also,
upon the petition of any person, the Secretary of HHS may promulgate regu-
lations to modify the Table. 54 This provision will permit claimants to seek
to prove that an injury not listed in the Table is nevertheless vaccine-related.
B. Dispute Resolution Process
The no-fault system established is to be administered by the federal dis-
trict courts.'" Each court must designate a special master who is to make
an initial determination as to whether or not a claimant is entitled to com-
pensation.' 56 The special master will use the Vaccine Injury Table to make
this determination.
If a claimant is not awarded compensation he may elect to accept the
judgment or to sue.' 57 If he receives an award, he must irrevocably choose
whether to accept the award or to sue.' 58 If he chooses to sue, the suit will
be governed by the applicable state law,'5 9 with three modifications. The
modifications involve the liability of manufacturers.
First, a manufacturer cannot be held liable for unavoidable side effects if
the vaccines are prepared and packaged pursuant to FDA directions."6 The
manufacturer will be held liable if the claimant can show wrongful conduct
or a failure to exercise due care even though the manufacturer complied with
FDA requirements.' 6' Second, vaccine manufacturers cannot be held liable
for failure to provide direct warnings to the injured party. 162 Finally, the
cases are to be tried in three stages; the first to determine liability, the second
to determine compensation and damages, and the last to determine punitive
damages.' 63 All of these restrictions on the liability of manufacturers will
serve to provide predictability in the estimation of costs for compensating
those who are injured as a result of vaccination.
C. Administrative Requirements
The legislation is to apply to all claims for damages in excess of $1,000
153. Id.
154. Id. at § 2114(c), 100 Stat. at 3766.
155. Id. at § 2112(a), 100 Stat. at 3761.
156. Id.






163. Id. at § 2123, 100 Stat. at 3774.
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arising after the effective date.' 64 In addition, any person who filed a civil
action prior to the effective date may, at any time within two years after the
effective date or before judgment, whichever comes first, withdraw the action
without prejudice and file a petition under the program. 165 Also, if the in-
jured party brought suit prior to the enactment of the program and was
denied relief he may file a petition under the program.
166
There is no limitation on the retroactivity of the program. This will per-
mit claims by persons who were injured prior to the enactment date. There
are, however, limitations on the amount of compensation for pre-enactment
claims. 1
67
D. Limitations on Awards
Compensation under the program includes the following: actual un-
reimbursable medical expenses,' 68 remedial care, rehabilitation, special edu-
cation, vocational training, emotional or behavioral therapy, residential and
custodial care and service expenses, special equipment and certain related
travel expenses. 169 Recovery may be obtained for lost wages; for children
under the age of eighteen, compensation is to be determined on the basis of
the average earnings of workers in the private non-farm sector. 170 Damages
for pain and suffering are not to exceed $250,000.171
Two types of compensation are prohibited under the program. The first is
punitive damages. 172 The second is compensation to a person other than the
injured vaccinee for expenses other than health, education and welfare, with
two exceptions.' 73 An award may be made to the estate of a deceased and,
as aforementioned, payments may be made for lost wages.' 74 These meas-
ures will serve to keep down the costs of administering the program.*
Patricia Carmen Murray
164. Id. at § 211l(a), 100 Stat. at 3758-59.
165. Id.
166. Id.
167. Id. at § 2115(b), 100 Stat. at 3769.
168. Id. at § 2115(a), 100 Stat. at 3767.
169. Id.
170. Id. at § 2115(a), 100 Stat. at 3768.
171. Id.
172. Id. at § 2115(d), 100 Stat. at 3768.
173. Id.
174. Id. at § 2115(a), 100 Stat. at 3767.
* On Thursday March 5, 1987 the Reagan Administration told Congress that it favors a
total overhaul of last year's childhood vaccine protection law. Administration Attacks Vaccine
Law, Wash. Post, Mar. 6, 1987, at A6, col. 1.
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